Zahra Aeman, Sisu Cristina, Silva Elisabete, De Aguiar Greca Sophie-Christine, Randeva Harpal S, Chatha Kamaljit, Kyrou Ioannis, Karteris Emmanouil
Biosciences, College of Health, Medicine and Life Sciences, Brunel University London, Uxbridge UB8 3PH, UK.
Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism (WISDEM), University Hospitals Coventry and Warwickshire NHS Trust, Coventry CV2 2DX, UK.
J Clin Med. 2020 Oct 14;9(10):3296. doi: 10.3390/jcm9103296.
Infection by the severe acute respiratory syndrome (SARS) coronavirus-2 (SARS-CoV-2) is the causative agent of a new disease (COVID-19). The risk of severe COVID-19 is increased by certain underlying comorbidities, including asthma, cancer, cardiovascular disease, hypertension, diabetes, and obesity. Notably, exposure to hormonally active chemicals called endocrine-disrupting chemicals (EDCs) can promote such cardio-metabolic diseases, endocrine-related cancers, and immune system dysregulation and thus, may also be linked to higher risk of severe COVID-19. Bisphenol A (BPA) is among the most common EDCs and exerts its effects via receptors which are widely distributed in human tissues, including nuclear oestrogen receptors (ERα and ERβ), membrane-bound oestrogen receptor (G protein-coupled receptor 30; GPR30), and human nuclear receptor oestrogen-related receptor gamma. As such, this paper focuses on the potential role of BPA in promoting comorbidities associated with severe COVID-19, as well as on potential BPA-induced effects on key SARS-CoV-2 infection mediators, such as angiotensin-converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2). Interestingly, GPR30 appears to exhibit greater co-localisation with TMPRSS2 in key tissues like lung and prostate, suggesting that BPA exposure may impact on the local expression of these SARS-CoV-2 infection mediators. Overall, the potential role of BPA on the risk and severity of COVID-19 merits further investigation.
严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）感染是一种新型疾病（2019冠状病毒病，COVID-19）的病原体。某些基础合并症会增加患重症COVID-19的风险，这些合并症包括哮喘、癌症、心血管疾病、高血压、糖尿病和肥胖症。值得注意的是，接触称为内分泌干扰化学物质（EDC）的激素活性化学物质会引发此类心血管代谢疾病、内分泌相关癌症以及免疫系统失调，因此，也可能与患重症COVID-19的较高风险有关。双酚A（BPA）是最常见的EDC之一，它通过广泛分布于人体组织中的受体发挥作用，这些受体包括核雌激素受体（ERα和ERβ）、膜结合雌激素受体（G蛋白偶联受体30；GPR30）以及人类核受体雌激素相关受体γ。因此，本文重点关注BPA在促进与重症COVID-19相关的合并症方面的潜在作用，以及BPA对关键的SARS-CoV-2感染介质（如血管紧张素转换酶2（ACE2）和跨膜丝氨酸蛋白酶2（TMPRSS2））的潜在诱导作用。有趣的是，GPR30在肺和前列腺等关键组织中似乎与TMPRSS2有更大程度的共定位，这表明接触BPA可能会影响这些SARS-CoV-2感染介质的局部表达。总体而言，BPA对COVID-19风险和严重程度的潜在作用值得进一步研究。
